Clinical Trial Update: Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 study of TBI-1301, an NY-ESO-1–specific TCR gene-transduced autologous T cell therapy, in solid tumors; the trial is currently active but not recruiting…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Esophageal Cancer
• Hepatocellular Carcinoma
• Lung Cancer
• Melanoma
• Ovarian Cancer
• Synovial Sarcoma

Drugs mentioned

• TBI-1301

Snippet

Sponsor: University Health Network, Toronto | Conditions: NY-ESO-1 Expressing Solid Tumors in HLA-A2 Positive Patients, Synovial Sarcoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING